/ /

  • linkedin
  • Increase Font
  • Sharebar

    Is genetic testing for cancer survivors underutilized?

    COG-SpecialDelivery-Issue_2641.jpg
     

    Mammographic density, hormonal therapy and breast cancer risk

    In postmenopausal women who start hormonal therapy with estrogen plus progestin (E+P), changes in breast density should be monitored as a possible bellwether of breast cancer risk, say the authors of a new study case-control study. The data are from the Women’s Health Initiative (WHI) and were published in The Journal of National Cancer Institute.

    The aim of the analysis was to determine whether mammographic density change associated with initiation of daily estrogen (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) predicts breast cancer risk. In 174 women who later developed breast cancer (cases) and 733 healthy women (controls), mammographic density was assessed with mammograms taken prior to and 1 year after randomization. Logistic regression analyses were used to adjust for confounders and baseline mammographic density, when appropriate.

    More: Failure to recommend genetic testing in breast cancer

    In women in the E+P arm (97 cases, 378 controls), breast cancer risk rose 3% for each 1% positive change in percent mammographic breast density (odds ratio [OR] =1.03; 95% confidence interval [CI] 1.01-1.06). Breast cancer risk increased 3.6-fold for women in the highest quintile of mammographic density change (> 19.3% increase) (95% CI 1.52-8.56). After adjusting for change in mammography density, the effect of E+P use on breast cancer risk (OR 1.28, 95% CI 0.90-1.82) was eliminated (OR 1.00, 95% CI 0.66-1.51).

    “The 1-year change in mammographic density after estrogen plus progestin initiation,” the authors said, “predicted subsequent increase in breast cancer risk.” They noted that all of the increased risk from E+P exposure was mediated through mammographic density change and encouraged physicians to evaluate changes in mammographic density in women who initiate the hormonal therapy and to discuss the breast cancer risk implications with them. 

    Miranda Hester
    Ms. Hester is Content Specialist with Contemporary OB/GYN and Contemporary Pediatrics.
    Judith M. Orvos, ELS
    Judith M. Orvos, ELS, is a a BELS-certified medical writer and editor and an editorial consultant for Contemporary OB/GYN.

    1 Comment

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • UBM User
      Barriers to Entry: CIGNA makes me, a board certified Ob/Gyn who personally is a BRCA carrier & utilizes NCCN guidelines, send to a GC (genetics counselor) to authorize BRCA-panel testing. Patients don't take the extra step to go or call to someone they don't know and thus CIGNA has effectively saved money which is their true mission statement! #Shameful!

    Poll

    Latest Tweets Follow